<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The pandemic of the coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. Patients can develop a lot of different manifestations, from asymptomatic form to severe acute respiratory distress syndrome (ARDS). Pulmonary fibrosis, as a primary cause of mortality, is the main consequence of lung injury caused by acute respiratory distress syndrome. Unfortunately, effective treatment for pulmonary fibrosis has not yet been found; that’s why we found an essential anti-fibrotic agent in the early acute phase of severe COVID-19 to fight the infection outcomes. This narrative review presents the therapeutic strategy and the importance of fighting pulmonary fibrosis to help patients worldwide protect themselves against severe and fatal viral infections. To prevent long-term sequelae and early mortality, it’s necessary to test the efficacy of anti-inflammatory drugs.</p>
</abstract>

The pandemic of the coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. Patients can develop a lot of different manifestations, from asymptomatic form to severe acute respiratory distress syndrome (ARDS). Pulmonary fibrosis, as a primary cause of mortality, is the main consequence of lung injury caused by acute respiratory distress syndrome. Unfortunately, effective treatment for pulmonary fibrosis has not yet been found; that’s why we found an essential anti-fibrotic agent in the early acute phase of severe COVID-19 to fight the infection outcomes. This narrative review presents the therapeutic strategy and the importance of fighting pulmonary fibrosis to help patients worldwide protect themselves against severe and fatal viral infections. To prevent long-term sequelae and early mortality, it’s necessary to test the efficacy of anti-inflammatory drugs.

Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

University of Medicine and Pharmacy “Grigore T. Popa”

Pulmonary Department, Faculty of General Medicine

University of Medicine and Pharmacy “Grigore T. Popa,”

Pneumologia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis"}

The pandemic of the coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. Patients can develop a lot of different manifestations, from...

Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

Publicado en línea: 19 jun 2024

Páginas: 90 - 96

DOI: https://doi.org/10.2478/pneum-2024-0014

Palabras clave
Coronavirus, lung fibrosis, Immune response, Respiratory syndrome, anti-fibrotic agent, Nintedanib

© 2023 Victoria Țau et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

Publicado en línea: 19 jun 2024

Páginas: 90 - 96

DOI: https://doi.org/10.2478/pneum-2024-0014

Palabras claveCoronavirus, lung fibrosis, Immune response, Respiratory syndrome, anti-fibrotic agent, Nintedanib

© 2023 Victoria Țau et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
Coronavirus, lung fibrosis, Immune response, Respiratory syndrome, anti-fibrotic agent, Nintedanib